anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is an open-label (all people know the identity of the intervention), multicenter (conducted in more than 1 center) and uncontrolled (no competitive drugs involved) study. Participants with SFI will receive treatment with ITCZ oral solution or switch treatment from intravenous (into a vein) infusion of itraconazole (ITCZ-intravenous) to ITCZ oral solution as per Investigator's discretion. All the participants with FN suspected of fungal infection will receive the switch treatment from ITCZ- intravenous to ITCZ oral solution. The study will include 3 periods: Pre-observation period (7 days), Treatment period (85 days for ITCZ oral solution monotherapy and 99 days for switch treatment) and Follow-up observation period (30 days). The participants who receive ITCZ oral solution monotherapy will receive ITCZ oral solution without ITCZ-intravenous in the dose range of 20 milliliter (ml) per day to 40 ml per day for 12 weeks (85 days) and those on the switch treatment will receive 400 milligram (mg) per day ITCZ-intravenous twice for first 2 days followed by 200 mg per day ITCZ-intravenous up to 14 days and then they will be administered treatment as per ITCZ oral solution monotherapy. Efficacy will primarily be evaluated by assessing the pharmacokinetics. Participants' safety will be monitored throughout the study.
Participants with non-small cell lung cancer (NSCLC), melanoma (MEL), head and neck squamous cell carcinoma (HNSCC), ovarian cancer (OvC), triple-negative breast cancer (TNBC), and esophageal carcinoma (EsC) received RO7296682 0.3 milligram (mg) intravenous (IV) infusion on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, every 3 weeks (Q3W). Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade \>=4, IRR; Grade \>=4, immune-mediated adverse events; Grade \>=4) were discontinued from study treatment.
The prevalence of chronic degenerative and inflammatory disorders, such as osteoarthritis, is constantly rising. As not all patients do respond adequately to the standard therapies, alternative treatment options such as low dose radiation therapy (LDRT) has gained further importance. LDRT is known to induce a long-lasting pain reduction, while having few side effects. Nonetheless, the detailed biological and immunological modes of action remain mostly elusive. In addition, there is a lack in placebo controlled randomised controlled trials (RCTs) proofing the pain-relieving effects of LDRT. So, the prospective, placebo-controlled, double-blind, randomized IMMO-LDRT02 trial to investigate the clinical efficacy of LDRT in the treatment of arthrosis should close this gap. Newly diagnosed or already existing arthroses of the fingers, wrists, shoulders, knees, ankles and feet will be enclosed. Finally, the evidence of clinical benefit from LDRT (6 x 0.5 Gy) will be compared to the placebo group (6 x 0 Gy), by determination via a visual analog scale (VAS) and identification of immunological changes, which contribute to the success of therapy and are specifically found in the test group (IMMO-LDRT01 trial; ClinicalTrials.gov Identifier: NCT02653079).
Chronic kidney disease (CKD) affects 10-15% of US adults including 30-40% of persons with diabetes mellitus (DM), is associated with poor outcomes, and often progresses to requiring dialysis or transplantation. Half of all Americans with CKD also have DM. While traditional and emerging pharmacotherapies are often used in CKD with diabetes (CKD/DM), the synergistic role of dietary interventions has not been well examined. Low-carbohydrate low-fat diets are often recommended in DM, whereas low-protein diets (LPDs) are recommended for non-diabetic CKD with increasing emphasis on plant-based protein sources. Evidence suggests that high-protein diets with greater animal protein content may lead to glomerular hyperfiltration and faster decline in renal function in patients with CKD/DM. There remains major controversy regarding the potential risks vs. benefits of plant-based diets in CKD/DM, for which guidelines remain based on expert opinion. Given conventional dietary restrictions for the management of DM, there is concern that plant-based LPDs may lead to protein-energy wasting and hyperkalemia, whereas these diets may indeed be most beneficial in patients with CKD/DM given their faster rates of CKD progression as compared to non-diabetics. At present, clinical practice guidelines provide conflicting recommendations regarding the amount (low vs. high) and source (plant vs. animal) of dietary protein intake (DPI) in CKD/DM. Given that prior dietary trials in CKD such as the 1994 Modification of Diet in Renal Disease (MDRD) study excluded CKD/DM and did not examine the optimal proportion of plant vs. animal-based proteins, there is urgent unmet need for a rigorous dietary intervention study to examine the efficacy and safety of patient-centered plant-based diets in CKD/DM.

The investigators will conduct a pilot feasibility randomized controlled trial in parallel with patients' routine follow-up visits at ambulatory clinics to test the feasibility and safety of implementing a Plant- Focused Nutrition in CKD/DM (PLAFOND) diet with a DPI of 0.6-0.8 g/kg/d comprised of \>2/3 plant-based sources, vs. standard-of-care renal diet with \<1/3 plant-sources and low-potassium content, administrated by dietitians, over a 6-month period in 120 patients with CKD/DM stage 3-5. The investigators will determine whether the PLAFOND diet vs. the standard-of-care renal diet can be adhered to with consistent separation in dietary protein and plant-based proportions at 3- and 6-months. The investigators will also examine nutritional status, physical performance, and body composition, as well as glycemic measures using traditional metrics and continuous glucose monitoring, while other biochemical parameters and patient-reported outcomes including CKD-related symptoms will also be studied. In addition to providing the requisite feasibility and safety data of patient-conduct of future multi-center trials, this study will have major immediate impact by reinvigorating the critical role of dietary management of CKD/DM.
The investigators will develop a new pedestrian hazard detection test and conduct a single arm interventional clinical trial to evaluate simulated low vision assistive devices in a sample of field loss subjects. Pedestrian detection performance with and without field expansion information will be tested and compared. The study will include 1 to 4 visits (each 2 to 4 hours) depending on the number of trials and experimental conditions (e.g., with and without simulated assistive devices) the subject is comfortable completing. The time between visits may vary depending on scheduling constraints and availability. During each visit, the subject will complete a series of simulated collision avoidance trials in VR requiring the detection and natural avoidance of a colliding pedestrian (alongside non-colliding pedestrians) while physically walking through an empty corridor. The study will be considered minimal-risk since there will be no physical obstacles that present actual collision risks.
1. A substantially pure composition separated from a plant cell, said composition is capable of activating the expression of a sesquiterpene synthase gene in a plant cell, wherein  (1) said composition is capable of activating the expression of a sesquiterpene synthase gene in said plant cell, after being treated with protease, pectinase, DNase or Rnase; (2) said composition is capable of activating the expression of a sesquiterpene synthase gene in said plant cell, after being lyophilized and reconstituted; (3) said composition does not partition into the organic phase following extraction with hexane; and (4) said composition comprises a diffusible compound having a molecular weight less than or equal to 10,000 daltons. 2. A composition of claim 1, wherein said compound is diffusible and has a molecular weight less than or equal to 1,000 daltons. 3. The composition of claim 1, wherein said sesquiterpene synthase is epi-5-aristolochene synthase. 4. The composition of claim 1, wherein said plant cell is selected from the group consisting of a tobacco cell, a tomato cell and a potato cell. 5. A method for preparing a composition which is capable of activating sesquiterpene synthase gene expression, said method comprising: a) contacting a plant cell with an elicitin under condition and with an amount that induces said cell to produce a composition which activates sesquiterpene synthase gene expression in a plant cell; and  b) recovering said elicitin-induced composition, which (1) is capable of activating the expression of a sesquiterpene synthase gene in said plant cell, after being treated with protease, pectinase, DNase or Rnase; (2) is capable of activating the expression of a sesquiterpene synthase gene in said plant cell, after being lyophilized and reconstituted; (3) does not partition into the organic phase following extraction with hexane; and (4) comprises a diffusible compound having a molecular weight less than or equal to 10,000 daltons. 6. The method of claim 5, wherein said compound is diffusible and has a molecular weight less than 1,000 daltons. 7. The method of claim 6, wherein said composition is recovered by dialysis. 8. The method of claim 5, wherein said elicitor is cryptogein. 9. The method of claim 5, wherein said plant cell is selected from the group consisting of a tobacco cell, a tomato cell and a potato cell. 10. The method of claim 5, wherein said sesquiterpene synthase is epi-5-aristolochene synthase. 11. The method of claim 5, wherein said composition is reduced by size fractioning.
Injectable compositions containing a suspension of trace elements insoluble in water, which are non-ionisable, and which are liberated slowly after intramuscular or subcutaneous injection by a moderated inflammatory process, esp. the free metals or their oxides, contain in addition an effective quantity of vitamin E (di - alpha - tocopheryl acetate). Used in treatment of disorders caused by trace element deficiency. Similar injections without vitamin E cause a painful inflammatory reaction esp. in cattle. The vitamin E prevents this. Typically the compositions contain metallic iron or manganese. In an example a composition contained 1000 mg metallic iron, particle size 44 microns, 3g tocopherol acetate, and purified olive oil to 10 ml. The dosage for 75-80 kg calves was 10 ml, and the animals showed no inflammation.
FIELD: medical engineering. SUBSTANCE: preparation is designed as carrier produced from chemically substance intact for organism and bearing information describing the medicinal preparation recorded thereon. The carrier is subjected to direct current magnetic field action at the moment the information is recorded. The device has testing circuit having electrodes and unit for measuring electric conductivity, unit for recording and reproducing the biologically significant information, as well as unit for storing the information as information unit. Units for recording and reproducing the biologically significant information additionally have antenna unit with amplifier. Unit for storing information has switching unit for connecting the information unit antenna to the circuit. The information unit is manufactured as at least one memory cell on the semiconductor silicon crystal as base. The method involves entering information about the medicinal preparation into the carrier intact for organism, acting with direct current magnetic field. The current of 8-12 mA and voltage of 5-9 V is applied. EFFECT: enhanced effectiveness of treatment; improved information supply. 4 cl, 1 dwg, 1 tbl
Echography and Elastography To determine physiological standards across age classes of myocardial stiffness estimated by Elastography in ultrafast (estimated right ventricular stiffness \[VD\] and left ventricular \[LV\]). This will be done in groups of children without heart condition, age group (10 children per group, four age groups \[0-1mois, 1 month-1 year 1 year-5 years, 5 years-15years\]).
This study consists of a screening period (up to 28 days), a treatment period (25 cycles) and a long term safety follow-up for participants until they are 5 years old or commence an alternative systemic NF1-PN treatment, whichever is the earlier. Participants may continue treatment with selumetinib throughout the long term safety follow-up as long as they are considered to be receiving clinical benefit in the opinion of their Investigator. A safety follow up assessment will be performed 30 days after the last dose of study intervention for all study participants.
A transdermal reservoir and a method of the present invention for loading a material into a reservoir includes providing an reservoir including a backing with an interior surface comprising a bibulous reservoir having a patient contact surface with a shape disposed on the interior surface of the backing. The method includes providing a closure sized and shaped to engage the backing for forming a releasable seal to isolate the bibulous reservoir from the ambient environment, the closure is removable from the housing to expose the patient contact surface for use. The provided closure has an inside surface with a section of an absorbent material disposed thereon. The provided section has a first surface so that when the closure is disposed on the backing, the absorbent material first surface is positioned in intimate physical contact with the reservoir. The method includes applying an aliquot of a material to the absorbent material. The method further includes placing the closure on the backing so that the first surface of said absorbent material is in intimate physical contact with the contact surface of the bibulous reservoir and the closure forms the releasable seal with the backing. The method includes allowing the reservoir—with the closure applied thereto to stand for a sufficient time to allow the aliquot of the material to be absorbed into the bibulous material thereby loading the reservoir.
PROBLEM TO BE SOLVED: To obtain a detergent composition containing a specific aliphatic acid hypotaurine salt as an essential component, giving excellent foaming and quality of foam with a slight pH dependence of foaming without creak feeling, stretching feeling and also a malodor, and useful for a shampoo and a detergent for cloths, etc. SOLUTION: This detergent composition contains a compound expressed by the formula: R-COO<-> H3 N<+> -CH2 -CH2 -SO2 <-> X<+> [R is a 7-23C (un)saturated hydrocarbon group; X is an alkali metal such as sodium, potassium and lithium or an organic alkali such as triethanolamine, diethanolamine and lysine] (e.g. hypotaurinesodium laurate or hypotaurine triethanolamine laurate) as an essential component in an amount of, e.g. 0.5-90wt.%. The compound of the formula is obtained by, e.g. dissolving an 8-24C fatty acid at 80 deg.C, adding an aqueous solution of hypotaurine and a prescribed alkali aqueous solution with separately stirring and reacting the resultant mixture.
This study was designed based on a cross-sectional investigation conducted Shanghai, China. Demographic characteristics, diaper utilization, Activities of Daily Living (ADL) and emotion were collected by Unified Needs Assessment Form for Elderly Care Questionnaire. Cognition function was assessed by Mini-mental State Examination (MMSE) scale. Multivariate logistic regression was used for statistical analysis. The diaper utilization rate was 31.2%. Female, higher level of education, poorer ADL and cognition, more severe incontinence and financial dependence on others were facilitating factors for diaper usage (P < 0.05). The possibility of using diaper differed according to the intimacy of caregivers. Among incontinent individuals with relatively good ADL and cognition level, diaper utilization can significantly decrease the risk of going out only once a month (OR: 2.63 vs 4.05), and going out less than once a month (OR: 5.32 vs 6.53). Incontinence people who going out at least once a week had a lower risk of some negative emotion. Significantly, diaper utilization further decreased this risk. In conclusion, for incontinence elderly people with relatively independent ability, proper use of diaper may improve the frequency of outdoor activity and emotion. Nevertheless, diaper utilization should be decided based on elderly people's own will.
Subjects recruited to the "Mentor" arm of the study are UCLA Pediatric Pain Program patients between the ages of 14 and 18. These mentors are identified by the Principal Investigator as children who have not necessarily eliminated pain, but have learned how to cope with pain and maintain appropriate functioning in daily life. Mentors undergo an in depth training from doctoral level psychologists who are members of the research team. Mentors present pain coping information developed by the research team, provide support, and encourage mentees to attend pain management therapies. They are also monitored by doctoral level psychologists throughout the duration of the study to ensure safety and appropriate contact with mentees via telephone.
This consists of 4 self-guided psycho-education modules supported by weekly telephone contact with a health professional trained in Acceptance and Commitment Therapy (ACT). Standard medical care will be provided as usual.
The present invention provides the nucleotide and amino acid sequences of canine IL-5. It also sets forth a recombinant DNA molecule, and conservative variants thereof, comprising the DNA sequence of canine IL-5, and recombinant vectors such as expression vectors, comprising a DNA sequence encoding canine IL-5. Further, the invention sets forth polypeptides produced using a recombinant expression vector containing a canine IL-5 sequence. Also disclosed are compositions comprising a nucleotide sequence that is antisense to a DNA sequence encoding a component of canine IL-5, wherein the component can be the full canine IL-5 protein. Disclosed are a cloning vector comprising a DNA sequence of canine IL-5 cDNA material; a recombinant cell line comprising a DNA sequence of the canine IL-5 cDNA material; a method for producing a polypeptide comprising a step of expressing a peptide comprising an amino acid sequence encoded by a cloning vector comprising canine IL-5 cDNA material; and a cell that expresses a recombinant polypeptide encoded by a DNA sequence (or conservative variants thereof) that encodes canine IL-5 or components thereof. Furthermore, antibodies that bind to canine IL-5, and mimetopes of IL-5 epitopes are also disclosed.
A method for generating evidence of a transfer event is provided. The method includes detecting a triggering event at a dispensing cabinet that includes a medication. The method also includes activating one or more monitoring devices to take the recording in response to detecting the triggering event. The recording includes a possible transfer event. The method also includes generating one or more transaction records associated with the recording. The method also includes filtering, at the database and based on the one or more transaction records, the plurality of recordings. The plurality of recordings includes recordings to determine whether a possible transfer event has occurred. In response to determining that a possible transfer event has occurred, the method includes generating an alert indicating that a possible transfer event has occurred. Related systems and articles of manufacture, including devices and computer program products, are also disclosed.
Peptide prodrugs of the general formula (I): X-L-Z, wherein X designates a pharmaceutically active peptide sequence, e.g. Leu-enkephalin; Z designates a peptide pre-sequence of 2 to 20 amino acid units, preferably comprising lysine and glutamic acid; and L is a linking group comprising from 3 to 9 backbone atoms, wherein the bond between the C-terminal carbonyl of X and L is different from a C-N amide bond. Preferably, the bond between X and L is an ester bond. It has been found that it is possible to obtain a remarkable increase in the resistance towards degradation by proteolytic enzymes such as carboxypeptidase A, pepsin A, leucine aminopeptidase, .alpha.-chymotrypsin when masking a pharmaceutically active peptide as a prodrug of the formula (I). The prodrugs of formula (I) are cleaved by the blood plasma enzyme butyryl cholinesterase indicating a readily bioreversibility. It is believed that the stability towards enzymatic cleavage is due to an induced helix-like structure.
BACKGROUND: Deodorants are widely used to mask unpleasant body odors. They are reported to cause some adverse effects depending on the form and ingredients. The purpose of this study was to assess the prevalence of deodorant use and related adverse effects among Palestinian students.
METHODS: This cross-sectional study was carried out at An-Najah National University from Aug 2018 to Mar 2020. A questionnaire was constructed using a Google survey form. All analyses were done using SPSS 21.0, Fisher test was used for comparative analysis and the P-value < 0.05 was considered as statistically significant.
RESULTS: A total of 554 students participated in the study. About 93% of the participants were using deodorants and adverse effects were reported by 25% of the participants. The reported adverse effects were itching (26%), coloration (25%), sneezing (21%), and eye redness (8%). Only 4.1% of the participants visited a physician for counselling regarding various adverse effects.
CONCLUSION: Deodorants were widely used by Palestinian students with reported adverse effects, but these side effects rarely prompted the participants to seek medical advice.
Although conventional intervention to microglia can mitigate neuroinflammation in the short term, immune disorders by peripheral inflammatory cells can infiltrate continuously, resulting in an overactivated immune microenvironment of Parkinson's disease (PD). Here, we design engineered extracellular vesicle-based nanoformulations (EVNs) to address multiple factors for the management of PD. Specifically, EVN is developed by coating CCR2-enriched mesenchymal stem cell-derived extracellular vesicles (MSCCCR2 EVs) onto a dihydrotanshinone I-loaded nanocarrier (MSeN-DT). The MSCCCR2 EVs (the shell of EVN) can actively show homing to specific chemokines CCL2 in the substantia nigra, which enables them to block the infiltration of peripheral inflammatory cells. Interestingly, MSeN-DT (the core of EVN) can promote the Nrf2-GPX4 pathway for the suppression of the source of inflammation by inhibiting ferroptosis in microglia. In the PD model mice, a satisfactory therapeutic effect is achieved, with inhibition of peripheral inflammatory cell infiltration, precise regulation of inflammatory microglia in the substantia nigra, as well as promotion of behavioral improvement and repairing damaged neurons. In this way, the combinatorial code of alleviation of inflammation and modulation of immune homeostasis can reshape the immune microenvironment in PD, which bridges internal anti-inflammatory and external immunity. This finding reveals a comprehensive therapeutic paradigm for PD that breaks the vicious cycle of immune overactivation.
Participants will self-serve and condiment a cold meal in the laboratory using an optimised portion control toolkit. This toolkit will include two calibrated serving spoons, one for vegetables (slotted) and one for starch (solid), and a calibrated oil dispenser. Both spoons have a volume capacity of 155 ml with a 121 ml mark. The oil dispenser has a volume capacity of 250ml and allows pre-portioning of the oil via a sucking device in amounts ranging from 5-20 millilitres, 1-3 teaspoons or 0.5 to 1 tablespoon, prior to serving. Participants will complete an eye-tracking test before eating, and will fill in questionnaires and provide blood samples during and after the meal. At 2h post-meal, they will complete a computerized memory reconstruction task related to the meal. After leaving the laboratory participants will keep a food diary, and will complete an on-line learning test before bedtime.